Smartphone App for Colorectal Cancer Screening

(SHIELD-TX Trial)

This trial explores how a new blood-based screening test for colorectal cancer (CRC) might encourage more people to adhere to regular screening schedules. Researchers aim to determine if a smartphone app can improve follow-up, particularly for those needing further testing after a positive result. Participants will either use the app for reminders and information or receive standard support without it. Ideal candidates are individuals without a history of CRC who have recently seen their doctor and have access to a specific healthcare app. As an unphased trial, this study provides a unique opportunity to contribute to innovative approaches in CRC screening and patient follow-up.

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial team or your doctor.

Research shows that blood tests for screening colorectal cancer are generally safe. Studies have found that these tests are approved for detecting colorectal cancer, with an accuracy of 83% in identifying the disease. This indicates that the tests are reliable and have passed safety checks for approval.

Researchers are excited about the smartphone app intervention for colorectal cancer screening because it leverages digital technology to enhance patient engagement and education. Unlike traditional methods that rely heavily on direct patient-provider interactions, this app sends educational messages directly to patients via their healthcare portal smartphone app. This approach aims to improve the rate at which patients follow up on positive blood test results by making information more accessible and timely. By potentially increasing the adherence to follow-up procedures like colonoscopies, the app could lead to earlier detection and treatment of colorectal cancer, which is crucial for better patient outcomes.

Research has shown that blood-based screening tests (BBST) for colorectal cancer (CRC) are promising tools. One study found that these tests accurately identify 83% of CRC cases and correctly rule out 90% of those without cancer. This means they effectively detect real cancer cases with minimal false alarms. Although they may not be as effective at spotting advanced precancerous growths, they do aid in early cancer detection. Early detection is crucial because it makes treatment easier and more effective. BBSTs can also encourage more people to get screened, which is important for catching cancer before it worsens.